RT Journal Article
SR Electronic
T1 Clinical Pilot of Bacterial Transcriptional Profiling as a Combined Genotypic and Phenotypic Antimicrobial Susceptibility Test
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.10.24310021
DO 10.1101/2024.07.10.24310021
A1 Young, EL
A1 Roach, DJ
A1 Martinsen, MA
A1 McGrath, GEG
A1 Holbrook, NR
A1 Cho, HE
A1 Seyoum, EY
A1 Pierce, VM
A1 Bhattacharyya, RP
YR 2024
UL http://medrxiv.org/content/early/2024/07/10/2024.07.10.24310021.abstract
AB Brief Summary Exposure to antibiotics causes differential transcriptional signatures in susceptible vs. resistant bacteria. These differences can be leveraged to rapidly predict resistance profiles of Escherichia coli and Klebsiella pneumoniae in clinical positive blood cultures.Antimicrobial resistance is a growing health threat, but standard methods for determining antibiotic susceptibility are slow and can delay optimal treatment, which is especially consequential in severe infections such as bacteremia. Novel approaches for rapid susceptibility profiling have emerged that characterize either bacterial response to antibiotics (phenotype) or detect specific resistance genes (genotype). GoPhAST-R is a novel assay, performed directly on positive blood cultures, that integrates rapid transcriptional response profiling with detection of key resistance gene transcripts, thereby providing simultaneous data on both phenotype and genotype. Here, we performed the first clinical pilot of GoPhAST-R on 42 positive blood cultures: 26 growing Escherichia coli, 15 growing Klebsiella pneumoniae, and 1 with both. An aliquot of each positive blood culture was exposed to 9 different antibiotics, lysed, then underwent rapid transcriptional profiling on the NanoString® platform; results were analyzed using an in-house susceptibility classification algorithm. GoPhAST-R achieved 95% overall agreement with standard antimicrobial susceptibility testing methods, with the highest agreement for beta-lactams (98%) and the lowest for fluoroquinolones (88%). Epidemic resistance genes including the extended spectrum beta-lactamase blaCTX-M-15 and the carbapenemase blaKPC were also detected within the population. This study demonstrates the clinical feasibility of using transcriptional response profiling for rapid resistance determination, although further validation with larger and more diverse bacterial populations will be essential in future work. GoPhAST-R represents a promising new approach for rapid and comprehensive antibiotic susceptibility testing in clinical settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Massachusetts General Hospital Pilot Translational Research Grant (to RPB and VMP), the Broad Institute NextGen Award (to RPB), the National Institutes of Health (1R01AI153405, to RPB), and the John G. Bartlett Fellowship of the Antibiotic Resistance Leadership Group (T32AI007061-44, to DJR). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical blood culture aliquots were collected under Mass General Brigham Institutional Review Board protocol 2015P002215.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data generated and the code used for analysis are available on GitHub at https://github.com/broadinstitute/Go-PhAST-R_Clinical_Pilot/https://github.com/broadinstitute/Go-PhAST-R_Clinical_Pilot/